Bluebird bio neuro disorder gene therapy gets FDA panel nod, awaits meeting on another | Seeking Alpha
bluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States
bluebird bio submits BLA for single-dose gene therapy to treat beta-thalassemia
Bristol Myers Squibb - Bristol Myers Squibb and bluebird bio Provide Regulatory Update on Idecabtagene Vicleucel (ide-cel, bb2121) for the Treatment of Patients with Multiple Myeloma
bluebird bio | LinkedIn
Bluebird Bio Resumes Marketing Of Gene Therapy Zynteglo For β-Thalassaemia In Europe – TIF
EU go-ahead for bluebird bio gene therapy for CALD
bluebird bio to split into two independent companies
Stock Down 98% From Peak, Bluebird Bio Could Run Out Of Cash
Why Bluebird Bio Stock Is Sinking This Week | The Motley Fool
Cooley's Anemia Foundation - Bluebird bio has provided updated findings on the case of Acute Myeloid Leukemia (AML) that was recently reported in its sickle cell disease (SCD) gene therapy program. These
Biogen's Aduhelm | Nordisk's Wegovy | Bluebird's Gene Therapy
Bluebird Bio's gene therapy has defeated one genetic disease – many more await
Bristol Myers Squibb And Bluebird Bio Announce Submission Of Biologics License Application (BLA) For Anti-BCMA CAR T-Cell Therapy Idecabtagene Vicleucel (Ide-Cel, bb2121) To FDA
bluebird bio | LinkedIn
Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel (Ide-cel, bb2121) for Adults with Relapsed and Refractory Multiple Myeloma | Business Wire
Bluebird's Gene Therapy; Neurocrine-Sosei's Pact; Twist-Abveris's Deal
bluebird bio and Gritstone Oncology to Collaborate | INN
press releases - bluebird bio, Inc.
SEC Filing - bluebird bio, Inc.
bluebird bio: Potential For 3 Gene Therapy Approvals (NASDAQ:BLUE) | Seeking Alpha
Erroneous announcement about bluebird's LentiGlobin prompts correction from company - MedCity News
Bluebird bio cuts 30% of its workforce as gene therapy dreams dashed in Europe, delayed in US | Fierce Pharma
bluebird bio Completes Oncology Spin-Off Business, Establishes New Nest | BioSpace
